[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600840":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":42,"collaborators":25,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":25,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":25,"enrollmentInfo":54,"targetDuration":25,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":25,"overallStatus":63,"whyStopped":25,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Handok Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HD-P023","EXPERIMENTAL","One tablet of HD-P023 by oral",[13],"Drug: HD-P023",{"label":15,"type":16,"description":17,"interventionNames":18},"Co-administration of Teneligliptin and Empagliflozin High","ACTIVE_COMPARATOR","One tablet each of Teneligliptin and Empagliflozin High by oral",[19],"Drug: Teneligliptin and Empagliflozin",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Single dose administration of HD-P023",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Teneligliptin and Empagliflozin","Single does administration of Teneligliptin and Empagliflozin High",[15],[31],{"facility":32,"status":25,"city":33,"state":25,"zip":34,"country":35,"countryCode":25,"cosmosGeoPoint":36,"geoPoint":41,"contacts":25},"H Plus Yangji Hospital","Seoul","08779","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},{"type":43,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100600840","phase-1-pharmacokinetics-and-safety-of-hd-p023-and-co-administration-of-teneligliptin-and-empagliflozin-high-in-healthy-volunteers-100600840",false,"NCT07102719","Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers","A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Coadministration of Teneligliptin and Empagliflozin High in Healthy Volunteers","Inclusion Criteria:\n\n* Patients who are 19 years or older on screening\n* Signed informed consent\n* Healthy Volunteer\n* Other inclusion applies\n\nExclusion Criteria:\n\n* Clinically relevant\u002Fsignificant findings as evaluated by the investigator\n* Other exclusion applied",true,"ALL","19 Years",{"count":55,"type":56},40,"ACTUAL","INTERVENTIONAL",[59],"PHASE1","The purpose of this study is to compare the pharmacokinetics and safety of HDP023 and coadministration of Teneligliptin and Empagliflozin in healthy adult volunteers",[62],"Healthy Volunteers","COMPLETED","2026-02-03",{"date":66,"type":56},"2026-02-05",{"date":68,"type":56},"2025-09-10",{"date":70,"type":56},"2025-10-20",{"name":5,"class":6},1]